Hyperfine Inc (HYPR) — Titan Protect Analysis

HYPR

Hyperfine Inc

Healthcare · ·

$1.38

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$149M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.43

Based on estimated future earnings — lower means cheaper

Rev Growth

+82.6%

Year-over-year revenue change

Profit Margin

-226.9%

How much profit the company keeps from each dollar of revenue

ROE

-89.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.00

+45% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About Hyperfine Inc

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departm

https://www.hyperfinemri.com

Country: United States Employees: 102 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.733

Good returns relative to risk taken

Kelly Fraction

0.0150

Marginal edge — very small allocation suggested

Calmar Ratio

0.399

Drawdown risk outweighs the returns — higher risk profile

Annual Return

27.2%

Historical annualised return based on price data

Max Drawdown

-68.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

137

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.22

38% below the year high

52W Low

$0.61

125% above the year low

Avg Volume

621,730

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

38.19

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

51.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-219.3%

Profit from core operations before interest and tax

Free Cash Flow

$-16,274,000

Negative — the business is spending more than it generates

Revenue (TTM)

$15M

Total revenue over the last 12 months

Net Income

$-34,779,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$2.50

Target Median

$2.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go